Abstract

The murine breast cancer cells (4T1) grown both in female BALB/c mice and in culture were treated with anastrozole (50 $\mu$ g/mL), tamoxifen citrate (5 $\mu$ g/mL), and the combination of the two drugs in order to determine treatment efficacies, toxic potential, and the mechanism of cell death. The in vivo treatments were evaluated by monitoring tumor growth, development, and life span. The in vitro effects were measured through cell growth kinetics, cell proliferation, mitochondrial membrane potential disruption assay, and light and scanning electron microscopy. All drug treatments extended the mean life span of the 4T1-inoculated tumor-bearing mice; however, only tamoxifen and combination treatments statistically increased the life span when compared to untreated mice. Although the most drug inhibitory effect on cell multiplication was observed in the combination treatment, both anastrozole and tamoxifen individually inhibited cell proliferation significantly at most time periods in this mouse breast cancer cell line. The mitochondrial membrane potential disruption assay demonstrated significant increase in the percent of cells undergoing apoptosis in all treatment groups. However, the combination treatment was the most effective in inducing cell death via apoptosis. Light and scanning electron microscopy of the treated cells revealed characteristics such as rounding, clumping, and shrinkage of the cells as well as formation of cell surface blebbing and apoptotic bodies suggestive of cell death via apoptotic pathway.

Highlights

  • For the past twenty years, tamoxifen has been the drug of choice for the treatment of advanced-stage estrogen receptor positive (ER-positive) breast cancers [1, 2]

  • We evaluated the effectiveness of anastrozole, tamoxifen, and the combination on 4T1 cells’ ability to induce tumors in BALB/c female mice

  • The combination treatment extended the life spans of the mice which were found to be statistically different from the untreated group (P < .05) but not from either the anastrozole- or tamoxifen-treated groups

Read more

Summary

Introduction

For the past twenty years, tamoxifen has been the drug of choice for the treatment of advanced-stage estrogen receptor positive (ER-positive) breast cancers [1, 2]. This antibreast cancer drug is often successful in limiting breast cancer growth initially, but continued use of the drug was known to stimulate disease progression [3, 4]. In 1995, anastrozole was originally approved by the Food and Drug Administration (FDA) as the first nonsteroidal aromatase inhibitor for the treatment of tamoxifen-resistant ERpositive breast cancer [8, 9]. Anastrozole was shown to shrink tumor size allowing previously inoperable breast cancers to become operable [13]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call